AR105482A1 - Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso - Google Patents

Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso

Info

Publication number
AR105482A1
AR105482A1 ARP160101896A ARP160101896A AR105482A1 AR 105482 A1 AR105482 A1 AR 105482A1 AR P160101896 A ARP160101896 A AR P160101896A AR P160101896 A ARP160101896 A AR P160101896A AR 105482 A1 AR105482 A1 AR 105482A1
Authority
AR
Argentina
Prior art keywords
prrsv
recombinant
vectors
vector
gp5a
Prior art date
Application number
ARP160101896A
Other languages
English (en)
Inventor
Kassa Aemro
Kim Taejoong
Mebastsion Teshome
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of AR105482A1 publication Critical patent/AR105482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/082—Arteriviridae, e.g. EAV, PRRSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vacunas o composiciones recombinantes del virus del síndrome reproductor y respiratorio porcino (PRRSV). En particular, abarca vectores de adenovirus recombinantes que codifican y expresan antígenos, proteínas, epitopes o inmunógenos gp2, gp3, gp4, gp5a, gp5 y/o E del PRRSV. Dichas vacunas o composiciones se pueden utilizar para proteger a los animales contra el PRRSV. Reivindicación 10: Un vector de Ad5-PRRSV recombinante caracterizado porque comprende, consiste esencialmente en o consiste en uno o más polinucleótidos que codifican para uno o mas antígenos, polipéptidos, ectodominios de gp2, gp3, gp4, gp5a, gp5 o E de PRRSV o variantes de los mismos, o una combinación de los mismos. Reivindicación 18: Un método para producir una respuesta protectora contra PRRSV en un animal no humano que lo necesite, caracterizado porque comprende administrar al animal un vector de Ad5-PRRSV recombinante que expresa por lo menos un antígeno, polipéptido, ectodominio, de gp2, gp3, gp4, gp5a, gp5 o E de PRRSV, o variantes de los mismos, y un transportador, adyuvante, excipiente o vehículo farmacéuticamente o veterinariamente aceptable; y/o en donde la administración es por ruta oro-nasal, aspersión, agua de bebida, intramuscular, o por administración subcutánea, intradérmica, transdérmica; y/o en donde la administración es por cebado y refuerzo; y/o en donde la primera vacunación es una mezcla de dos vectores Ad5, en donde el primer vector Ad5 expresa proteínas menores de PRRSV redirigidas y el segundo vector Ad5 expresa proteínas mayores de PRRSV; y en donde el refuerzo comprende o consiste esencialmente en ambos vectores de la primera vacunación, o bien alguno de los vectores solos; y/o en donde el animal es un porcino.
ARP160101896A 2015-06-23 2016-06-23 Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso AR105482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562183410P 2015-06-23 2015-06-23

Publications (1)

Publication Number Publication Date
AR105482A1 true AR105482A1 (es) 2017-10-11

Family

ID=56409166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101896A AR105482A1 (es) 2015-06-23 2016-06-23 Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso

Country Status (20)

Country Link
US (2) US9981033B2 (es)
EP (3) EP3738975A1 (es)
JP (1) JP2018523993A (es)
CN (1) CN107922462B (es)
AR (1) AR105482A1 (es)
AU (2) AU2016282772B2 (es)
BR (1) BR112017027895A2 (es)
CA (1) CA2990643C (es)
CL (1) CL2017003341A1 (es)
DK (1) DK3313864T3 (es)
EA (1) EA201890110A1 (es)
ES (1) ES2902491T3 (es)
HK (1) HK1253863A1 (es)
MX (2) MX2017016895A (es)
NZ (1) NZ738957A (es)
PH (1) PH12017502380A1 (es)
PL (1) PL3313864T3 (es)
TW (1) TWI737617B (es)
WO (1) WO2016210094A1 (es)
ZA (1) ZA201708638B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990643C (en) * 2015-06-23 2023-10-17 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
PE20191701A1 (es) * 2016-12-14 2019-11-27 Boehringer Ingelheim Animal Health Usa Inc Vectores recombinantes de hvt que expresan multiples antigenos de patogenos de aves y sus usos
MX2017008751A (es) * 2017-06-29 2019-02-08 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Proteína quimérica para la prevención y el diagnóstico del síndrome respiratorio y reproductivo porciono (prss).
CN109395073B (zh) * 2018-11-07 2019-10-25 陕西诺威利华生物科技有限公司 一种免疫增强型重组prrsv病毒样颗粒亚单位疫苗
CN115043913B (zh) * 2022-06-30 2024-08-16 国药集团动物保健股份有限公司 一种蛋白组合物、其制备方法及其应用
CN115785286B (zh) * 2022-12-05 2023-07-14 北京标驰泽惠生物科技有限公司 一种猪繁殖与呼吸综合征病毒的融合蛋白及其应用
CN116948044A (zh) * 2023-07-27 2023-10-27 广州乐康生物医药科技有限公司 一种猪繁殖与呼吸综合症病毒基因工程亚单位疫苗

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US6773908B1 (en) * 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
ES2262142T3 (es) * 1994-08-05 2006-11-16 Regents Of The University Of Minnesota Secuencia virica de nucleotidos de vr-2332 y metodos de uso.
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
DE69703974T2 (de) 1996-10-17 2001-07-19 Oxford Biomedica (Uk) Ltd., Oxford Retrovirale vektoren
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
ATE365746T1 (de) 1997-05-06 2007-07-15 Boehringer Ingelheim Vetmed Prrsv-antigene, die auf peptidsequenzen des prrs- virus basieren, für die verwendung als impfstoff und für diagnostische tests
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US7256180B2 (en) * 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
EP1962900A2 (en) * 2005-11-29 2008-09-03 Iowa State University Research Foundation, Inc. Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof
US7465455B2 (en) * 2006-07-05 2008-12-16 Healthbanks Biotech Co., Ltd. Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine
CN101209351B (zh) * 2006-12-31 2011-05-18 武昌船舶重工有限责任公司 猪繁殖与呼吸综合征-安卡拉牛痘病毒基因工程疫苗
US8142788B2 (en) 2007-04-30 2012-03-27 Mj Biologics, Inc. PRRSV GP5 based compositions and methods
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
CA2800824A1 (en) * 2010-06-02 2011-12-08 Virginia Tech Intellectual Properties, Inc. Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)
CN102107003A (zh) * 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
WO2012108840A1 (en) * 2011-02-08 2012-08-16 Temasek Life Sciences Laboratory Limited A novel expression cassette for efficient surface display of antigenic proteins
AU2011384799A1 (en) * 2011-12-30 2014-07-03 United Biomedical, Inc. Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (PRRS)
CN103421817B (zh) * 2012-10-15 2016-01-13 华中农业大学 人工合成的猪繁殖与呼吸综合征病毒多表位基因及应用
CN103992408A (zh) * 2014-03-24 2014-08-20 青岛宝麦德生物医药科技有限公司 一种蓝耳病蛋白工程疫苗的制备
CA2990643C (en) * 2015-06-23 2023-10-17 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof

Also Published As

Publication number Publication date
ZA201708638B (en) 2019-08-28
US9981033B2 (en) 2018-05-29
PH12017502380A1 (en) 2018-06-25
EP3313864B1 (en) 2021-07-28
CN107922462A (zh) 2018-04-17
WO2016210094A1 (en) 2016-12-29
DK3313864T3 (da) 2021-11-01
EP3313864A1 (en) 2018-05-02
EP3738975A1 (en) 2020-11-18
US20160375122A1 (en) 2016-12-29
ES2902491T3 (es) 2022-03-28
US20180243398A1 (en) 2018-08-30
EA201890110A1 (ru) 2018-05-31
CA2990643A1 (en) 2016-12-29
AU2016282772B2 (en) 2019-09-05
AU2019275585B2 (en) 2022-01-27
NZ738957A (en) 2019-09-27
AU2019275585A1 (en) 2020-01-02
TW201713358A (zh) 2017-04-16
EP3889166A1 (en) 2021-10-06
JP2018523993A (ja) 2018-08-30
CN107922462B (zh) 2022-03-18
US10751407B2 (en) 2020-08-25
AU2016282772A1 (en) 2018-02-01
MX2022000222A (es) 2022-02-03
MX2017016895A (es) 2018-04-10
BR112017027895A2 (pt) 2018-11-06
HK1253863A1 (zh) 2019-07-05
PL3313864T3 (pl) 2022-01-03
CL2017003341A1 (es) 2018-07-13
TWI737617B (zh) 2021-09-01
CA2990643C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
AR105482A1 (es) Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
BR112018012962A2 (pt) vacinas de zika recombinantes
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
CL2019000704A1 (es) Vectores de adenovirus canino.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
MX2021015465A (es) Vacuna para fiebre porcina africana.
RU2015135890A (ru) Композиция вакцины
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
EA201892735A1 (ru) Состав вакцины против hiv
AR095482A1 (es) Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso
WO2019021305A1 (en) VACCINE AGAINST FOOT AND MOUTH DISEASE
EA201790296A1 (ru) Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9
ES2387321T3 (es) Proteína de fusión no estructural del virus de la hepatitis C
EA202000369A1 (ru) ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКОГО СРЕДСТВА ДЛЯ ИНДУКЦИИ СПЕЦИФИЧЕСКОГО ИММУНИТЕТА ПРОТИВ ВИРУСА ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА SARS-CoV-2 (ВАРИАНТЫ)
RU2008138536A (ru) Химерные вакцинные антигены против вируса классической чумы свиней
Stepanova et al. A fusion protein based on the second subunit of hemagglutinin of influenza A/H2N2 viruses provides cross immunity
WO2014067498A1 (es) Antígenos vacunales quiméricos contra el virus de la hepatitis c
Zeng et al. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice
Wang et al. Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d
Eck et al. Virus replicon particles expressing porcine reproductive and respiratory syndrome virus proteins elicit immune priming but do not confer protection from viremia in pigs
Elahi et al. Investigation of the immunological properties of the bovine viral diarrhea virus protein NS3 expressed by an adenovirus vector in mice
JP2013512256A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure